

SAMSRITA LABS LIMITED

To,

Date: 13.08.2026

1. BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001 Scrip Code: 539267	2. Metropolitan Stock Exchange of India Limited 205(A), 2 nd Floor, Piramal Agastya Corporate Park, Kamani Junction, LBS Road, Kurla (West), Mumbai-400 070 Symbol: SAMSRITA
--	---

Sub: Outcome of Board Meeting held on 13.08.2026 under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Unit: Samsrita Labs Limited

Dear Sir/Madam,

With reference to the above mentioned subject, this is to inform the Exchanges that the meeting of the Board of Directors of Samsrita Labs Limited held on Thursday, 13.08.2026 at the registered office of the Company situated at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad-500082, Telangana, the following items were Considered and approved.

1. Un-audited Standalone and Consolidated financial results for the quarter ended 30th June, 2026 (enclosed).
2. Limited Review Reports (Standalone and Consolidated) given by Statutory Auditors of the Company for the quarter ended 30th June, 2026 (enclosed)

The Board Meeting Commenced at 3.30 p.m and concluded at 4.00 p.m

This is for the information and records of the Exchanges, please.

Thanking you,

Yours sincerely

For Samsrita Labs Limited

K. Krishnam Raju
Chairman & Whole time Director
DIN: 00874650

Encl: As above

Regd.Off & Corp Off: 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad.500082.
L85110TG1996PLC099198,Emailid + info@drhlsl.com, pcproductsindia@gmail.com, cs@drhlsl.com
Contact No.9490424639, Website: www.drhlsl.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2026					
(INR In Lakhs)					
		Quarter Ended			Previous Year Ended 31- 03-2026
		3 Months Ended 30/6/2026	Preceding 3 Months Ended 31/03/2026	Corresponding 3 months ended in previous year 30/06/2025	
		UnAudited	Audited	UnAudited	Audited
I	Revenue from Operations	-	1.81	-	1.81
II	Other Income	-	3.15	-	3.15
III	Total Revenue (I+II)	-	4.96	-	4.96
IV	Expenses				
	Cost of Material Consumed	-	-	-	-
	Purchase of Stock-in-trade	-	1.65	-	1.65
	Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-
	Employee benefits expenses	9.80	7.83	15.53	39.11
	Finance Costs	-	-	-	-
	Depreciation and Amortisation expenses	0.12	0.03	0.03	0.14
	Other Expenses	21.55	7.32	12.10	832.66
	Total Expenses	31.47	16.83	27.66	873.56
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(31.47)	(11.87)	(27.66)	(868.60)
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(31.47)	(11.87)	(27.66)	(868.60)
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(31.47)	(11.87)	(27.66)	(868.60)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)				
XIII	Profit/ (Loss) for the period (IX+XII)	(31.47)	(11.87)	(27.66)	(868.60)
XIV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss		-		-
XV	period (XIII+ XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(31.47)	(11.87)	(27.66)	(868.60)
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	-	-
XVII	Comprehensive Income attributable to Owners of the company	(31.47)	(11.87)	(27.66)	(868.60)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.14)	(0.06)	(0.19)	(4.25)
	2) Diluted	(0.14)	(0.06)	(0.19)	(4.25)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)				
	1) Basic	(0.14)	(0.06)	(0.19)	(4.25)
	2) Diluted	(0.14)	(0.06)	(0.19)	(4.25)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,274.97	2,274.97	1,480.87	2,274.97

Notes:

1. The unaudited Standalone financial results for the quarter ended 30th June 2026 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Thursday, 13th August 2026.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
4. The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

For SAMSRITA LABS LIMITED

Place : Hyderabad

Date: 13/08/2026

K.Krishnam Raju

Chairman & Whole time Director (DIN 00874650)



Independent Auditor's Review Report on the Quarterly unaudited Standalone Financial results of Samsrita labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Samsrita Labs Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Samsrita Labs Limited ("the Company") for the quarter ended June 30, 2026 and year to date results for the period April 01, 2026 to June 30, 2026 ("the Statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with





4. Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.
5. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MGR & CO
Chartered Accountants
FRN:012787S

M.G Rao
Partner
M.No.029893
UDIN: 26029893UUYVNP8711
Place: Hyderabad
Date: 13/08/2026



CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2026					
(INR In Lakhs)					
		Quarter Ended			
		3 Months Ended 30/6/2026	Preceding 3 Months Ended 31/03/2026	Corresponding 3 months ended in previous year 30/06/2025	Previous Year Ended 31- 03-2026
		UnAudited	Audited	UnAudited	Audited
I	Revenue from Operations	-	1.81	-	1.81
II	Other Income	-	3.15	-	3.15
III	Total Revenue (I+II)	-	4.96	-	4.96
IV	Expenses				
	Cost of Material Consumed	-	-	-	-
	Purchase of Stock-in-trade	-	1.65	-	1.65
	Changes in inventories of finished goods, Work in progress and Stock in trade	-	-	-	-
	Employee benefits expenses	9.80	7.83	-	39.11
	Finance Costs	-	-	-	-
	Depreciation and Amortisation expenses	0.12	0.03	-	0.14
	Other Expenses	21.55	7.32	-	832.66
	Total Expenses	31.47	16.83	-	873.56
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(31.47)	(11.87)	-	(868.60)
VI	Exceptional Items	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(31.47)	(11.87)	-	(868.60)
VIII	Tax Expense:				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(31.47)	(11.87)	-	(868.60)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)				
XIII	Share of Profit (loss) of Associates and Joint ventures accounted for using equity method	12.60	(36.29)		52.55
XIV	Profit/ (Loss) for the period (IX+XIII)	(18.87)	(48.16)	-	(816.05)
XV	Other Comprehensive Income A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss (B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss		-		-
XVI	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(18.87)	(48.16)	-	(816.05)
XVII	Comprehensive Income attributable to Non Controlling Interest	-	-	-	-
XVIII	Comprehensive Income attributable to Owners of the company	(18.87)	(48.16)	-	(816.05)
XIX	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)				
	1) Basic	(0.08)	(0.06)	-	(3.99)
	2) Diluted	(0.08)	(0.06)	-	(3.99)
XX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each) 1) Basic 2) Diluted	-	-	-	-
XXI	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each) 1) Basic 2) Diluted	(0.08) (0.08)	(0.06) (0.06)	- -	(3.99) (3.99)
XXII	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	2,274.97	2,274.97	-	2,274.97

Notes:

1. The unaudited Consolidated financial results for the quarter ended 30th June 2026 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Thursday, 13th August 2026.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
4. The Company does not have any subsidiary. However, the Company has two associate companies, namely Krisani Bio Sciences Private Limited and Qrops Advisory Services Private Limited. Accordingly, the consolidated financial results comprise the financial results of Samsrita Labs Limited and its two associate companies.
5. The Previous year's/quarter's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

For SAMSRITA LABS LIMITED

Place : Hyderabad
Date: 13/08/2026

K.Krishnam Raju
Chairman & Whole time Director (DIN 00874650)



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Result for the Quarter ended on 30th June, 2026 of Samsrita labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
Samsrita labs Limited

1. We have reviewed the Accompanying Statement of Unaudited Consolidated Financial Result of Samsrita Labs Limited ("The Parent Company") and its Associate Companies, Krisani Bio Sciences private Limited and QROPS Advisory Services private Limited, together referred to as "The Group") for quarter ended 30th June, 2026 ("The Statement") attached herewith being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended), read with SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 9th July, 2019.

2. This statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit. Accordingly, we do not express an audit opinion.





4. The accompanying Statement also includes the unaudited interim financial results in respect of the following two Associate Companies, Krisani Bio Sciences Private Limited and QROPS Advisory Services Private Limited, whose unaudited interim consolidated financial results reflect an aggregate net loss of Rs. 18.87 Lakhs for the quarter ended 30th June, 2026, of which the Group's share of profit after tax amounts to Rs. 12.60 Lakhs for the quarter ended 30th June, 2026.

These unaudited interim consolidated financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these associates. Is based solely on such unaudited interim consolidated financial results. According to the information and explanations given to us by the Management.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards specified under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MGR & CO
Chartered Accountants
FRN:012787S

M.G Rao
Partner
M.No.029893
UDIN: 26029893MNEQCV8664
Place: Hyderabad
Date:13.08.2026

